サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1571451

原発性免疫不全症候群の市場規模、シェア、動向分析レポート：疾患別、治療法別、地域別、セグメント別予測、2024年～2030年

Primary Immunodeficiency Disorders Market Size, Share & Trends Analysis Report By Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders), By Treatment, By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
原発性免疫不全症候群の市場規模、シェア、動向分析レポート：疾患別、治療法別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年09月05日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

原発性免疫不全症候群市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の原発性免疫不全症候群市場規模は2030年までに111億4,000万米ドルに達する見込みです。

2024年から2030年までのCAGRは6.4%で拡大する見込みです。この業界は、複数の重要な要因によって大きな成長を遂げています。遺伝性疾患の罹患率の上昇、ヘルスケア専門家の意識の向上、診断・治療技術の進歩は、業界の拡大に極めて重要です。

2022年12月にニューイングランド・ジャーナル・オブ・メディシン誌に掲載された研究では、アルテミス欠損型重症複合免疫不全症（ART-SCID）に対する遺伝子治療の成功が注目されています。DCLRE1C遺伝子の健康なコピーを患者の幹細胞に加えることにより、この治療法はT細胞とB細胞の機能を効果的に回復させました。10人の幼児を対象としたこの研究では、従来の治療と比較して、著しい免疫回復と合併症の減少が見られました。この治療法の可能性について研究者たちは楽観的であるが、FDAの承認と多様な集団への適用性を検討するためには、さらなる長期的研究と広範な臨床試験が必要です。Artemis欠損型SCIDに対する遺伝子治療の成功は、これまで治療が困難であった疾患に対する効果的な治療を実証し、業界の成長を後押しします。この進歩は、遺伝子治療ソリューションと治療の革新に対する需要を促進します。この研究による肯定的な結果は、投資の増加、広範な採用、新しい治療法の開発につながる可能性があり、それによって先進的な治療法の産業が拡大します。

さらに、いくつかの薬剤の成功は、同様の技術革新の可能性を浮き彫りにし、業界の拡大を促進し、この分野における特殊な治療法のさらなる開発を促しています。例えば、2023年3月、ファーミング・グループのレニオリシブ（ジョエンハ）は、12歳以上の患者を対象とした活性化ホスホイノシチド3キナーゼデルタ症候群（APDS）の最初の治療薬としてFDAから承認されました。この承認は、レニオリシブがプラセボと比較してリンパ節サイズを縮小し、ナイーブB細胞数を37％改善したことを実証した12週間の試験に続くものです。遺伝子治療の進歩やレニオリシブのような新しい治療法の承認により、業界は拡大しています。これらの技術革新は、これまで治療が困難であった疾患に対する効果的な解決策を示すものであり、この分野への投資と関心を高める原動力となっています。こうした治療法の成功は市場の信頼を高め、専門的な治療法のさらなる開発を促します。研究が進み、新たな治療法が登場するにつれて、先進免疫不全症治療市場は力強い成長を続け、最終的には患者にも医療提供者にも利益をもたらすと期待されています。

原発性免疫不全症候群市場レポート・ハイライト

  • 地域別では、北米が2023年に45.39%の最大市場シェアを占めました。同市場は、強固なヘルスケアインフラ、高い有病率、同地域における政府の積極的な取り組みが牽引しています。
  • 疾患別では、抗体欠乏症が2023年に52.62%の最大シェアを占めました。この成長は、高い有病率、ヘルスケアへの大きな影響、的を絞った治療法の開発に起因しています。認知度の向上と高度な診断法も、業界における存在感を高めています。
  • 治療法別では、免疫グロブリン補充療法が最大のシェアを占めており、2023年には63.18％を占めました。効果的な治療に対する需要の高さ、治療の進歩、継続的な治療に対する重要なニーズが、同市場の大きなシェアに寄与しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 原発性免疫不全症候群市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • 原発性免疫不全症候群市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 原発性免疫不全症候群市場：疾患の推定・動向分析

  • セグメントダッシュボード
  • 原発性免疫不全症候群市場：疾患変動分析
  • 原発性免疫不全症候群市場：疾患別展望
  • 市場規模と予測・動向分析、2018年～2030年
  • 抗体欠乏症
  • 細胞性免疫不全症
  • 先天性免疫疾患
  • その他

第5章 原発性免疫不全症候群市場：治療法の推定・動向分析

  • セグメントダッシュボード
  • 原発性免疫不全症候群市場：治療法変動分析
  • 原発性免疫不全症候群市場：治療法別展望
  • 市場規模と予測・動向分析、2018年～2030年
  • 免疫グロブリン補充療法
  • 抗生物質療法
  • 幹細胞/骨髄移植
  • 遺伝子治療
  • その他

第6章 原発性免疫不全症候群市場：地域の推定・動向分析

  • 地域ダッシュボード
  • 原発性免疫不全症候群市場：地域変動分析
  • 原発性免疫不全症候群市場：地域別展望
  • 市場規模と予測・動向分析、2018年～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
    • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • ノルウェー
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 市場参入企業の分類
  • 主要企業プロファイル
    • Baxter International, Inc.
    • CSL Behring LLC
    • Takeda Pharmaceutical Company Limited
    • Octapharma
    • Biotest AG
    • Grifols, SA
    • Kedrion Biopharma Inc
    • Bio Products Laboratory Ltd
    • LFB SA
    • ADMA Biologics, Inc.
    • Abbott Laboratories
    • Astellas Pharma Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 4 Global primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 North America primary immunodeficiency disorders market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 7 North America primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 U.S primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 9 U.S primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 11 Canada primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 Mexico primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Mexico primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Europe primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 16 Europe primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 UK primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 18 UK primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 Germany primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 20 Germany primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 21 France primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 22 France primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 23 Italy primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 24 Italy primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Spain primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 26 Spain primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Denmark primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 28 Denmark primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 29 Norway primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 30 Norway primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 Sweden primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 32 Sweden primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Japan primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 37 Japan primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 China primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 39 China primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 40 India primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 41 India primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 43 Australia primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 South Korea primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 45 South Korea primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 Thailand primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 47 Thailand primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Latin America primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 49 Latin America primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 50 Latin America primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Brazil primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 52 Brazil primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 Argentina primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 54 Argentina primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 South Africa primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 59 South Africa primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 UAE primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 63 UAE primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 64 Kuwait primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 65 Kuwait primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Primary immunodeficiency disorders market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Primary immunodeficiency disorders market, disease outlook key takeaways, (USD Million)
  • Fig. 12 Primary immunodeficiency disorders market: disease movement analysis, 2023 & 2030 (USD Million)
  • Fig. 13 Antibody deficiency market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Cellular immunodeficiency market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Innate immune disorders market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Primary immunodeficiency disorders market, treatment outlook key takeaways, (USD Million)
  • Fig. 18 Primary immunodeficiency disorders market: treatment movement analysis, 2023 & 2030 (USD Million)
  • Fig. 19 Immunoglobulin replacement therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Antibiotic therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Stem cell/ bone marrow transplantation market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Gene therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Primary immunodeficiency disorders market: regional key takeaways (USD Million)
  • Fig. 25 Primary immunodeficiency disorders market: regional outlook, 2023 & 2030 (USD Million)
  • Fig. 26 North America Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 US Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Canada Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Europe Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 UK Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Germany Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 France Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Spain Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Italy Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Norway Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Asia Pacific Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 China Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 India Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 South Korea Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Australia Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Latin America Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Brazil Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Argentina Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Middle East and Africa Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Africa Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 UAE Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 List of key emerging company's/technology disruptors/innovators
目次
Product Code: GVR-4-68040-444-4

Primary Immunodeficiency Disorders Market Growth & Trends:

The global primary immunodeficiency disorders market size is expected to reach USD 11.14 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.4% from 2024 to 2030. The industry is experiencing significant growth, driven by multiple key factors. Rising incidences of genetic disorders, increased awareness among healthcare professionals, and advancements in diagnostic and therapeutic technologies are pivotal in expanding the industry.

A study published in The New England Journal of Medicine in December 2022 highlights the success of gene therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). By adding a healthy copy of the DCLRE1C gene to patients' stem cells, this therapy effectively restored T and B cell function. The study, involving 10 infants, showed significant immune recovery and reduced complications compared to traditional treatments. Researchers are optimistic about the therapy's potential, though further long-term studies and broader trials are needed for FDA approval and to explore its applicability in diverse populations. The successful gene therapy for Artemis-deficient SCID boosts industry growth by demonstrating effective treatment for previously difficult-to-treat conditions. This advancement drives demand for gene therapy solutions and innovations in treatments. The positive outcomes from this study potentially leading to increased investment, broader adoption, and the development of new therapies, thereby expanding the industry for advanced treatments.

Moreover, several drug's success highlights the potential for similar innovations, fostering industry expansion and encouraging further development of specialized therapies in the sector. For instance, in March 2023, Pharming Group leniolisib (Joenja) approved by the FDA as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older. The approval follows a 12-week study demonstrating that leniolisib reduced lymph node size and improved naive B cell counts by 37% compared to placebo. The industry is expanding due to advancements in gene therapy and the approval of new treatments such as leniolisib. These innovations demonstrate effective solutions for previously difficult-to-treat conditions, driving increased investment and interest in the sector. The success ofthese therapies boosts market confidence and encourages further development of specialized treatments. As research progresses and new therapies emerge, the market for advanced immunodeficiency treatments is expected to continue its robust growth, ultimately benefiting patients and healthcare providers alike.

Primary Immunodeficiency Disorders Market Report Highlights:

  • Based on region, North America accounted for largest market share of 45.39% in 2023. The market is driven by robust healthcare infrastructure, high prevalence, and proactive government initiatives in the region.
  • Based on disease, antibody deficiency segment accounted for the largest share of 52.62% in disease segment in 2023. The growth can be attributed to its high prevalence, significant healthcare impact, and the development of targeted treatments. Increased awareness and advanced diagnostics also contribute to its substantial presence in the industry.
  • Based on product, the immunoglobulin replacement therapy segment holds the largest share in the market accounted for 63.18% in 2023 owing to its essential role in managing antibody deficiencies. High demand for effective treatment, advancements in therapy, and the critical need for ongoing care contribute to its substantial market share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Treatment
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Treatment outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Primary Immunodeficiency Disorders Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Primary Immunodeficiency Disorders Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Primary Immunodeficiency Disorders Market: Disease Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Primary Immunodeficiency Disorders Market: Disease Movement Analysis
  • 4.3. Primary Immunodeficiency Disorders Market by Disease Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Antibody Deficiency
    • 4.5.1. Antibody Deficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Cellular Immunodeficiency
    • 4.6.1. Cellular Immunodeficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Innate Immune Disorders
    • 4.7.1. Innate Immune Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Primary Immunodeficiency Disorders Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Primary Immunodeficiency Disorders Market: Treatment Movement Analysis
  • 5.3. Primary Immunodeficiency Disorders Market by Treatment Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Immunoglobulin Replacement Therapy
    • 5.5.1. Immunoglobulin Replacement Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Antibiotic Therapy
    • 5.6.1. Antibiotic Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Stem Cell/Bone Marrow Transplantation
    • 5.7.1. Stem Cell/Bone Marrow Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Gene Therapy
    • 5.8.1. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Regional Primary Immunodeficiency Disorders Market movement analysis
  • 6.3. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis by Disease, Biomaterial & End-use
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. North America
    • 6.5.1. North America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. U.S. Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Canada Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Mexico Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Europe
    • 6.5.6. Europe Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. UK
      • 6.5.7.1. UK Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Germany
      • 6.5.8.1. Germany Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. France
      • 6.5.9.1. France Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.10. Italy
      • 6.5.10.1. Italy Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.11. Spain
      • 6.5.11.1. Spain Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.12. Denmark
      • 6.5.12.1. Denmark Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.13. Norway
      • 6.5.13.1. Norway Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.14. Sweden
      • 6.5.14.1. Sweden Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Japan Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. China Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. India Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. South Korea Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Australia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Thailand Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Brazil Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Argentina Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East & Africa
    • 6.8.1. Middle East & Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. South Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Saudi Arabia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. UAE Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Kuwait Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Key Company Profiles
    • 7.2.1. Baxter International, Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Disease benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. CSL Behring LLC
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Takeda Pharmaceutical Company Limited
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Octapharma
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Biotest AG
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Grifols, S.A.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Kedrion Biopharma Inc
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Bio Products Laboratory Ltd
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. LFB S.A
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. ADMA Biologics, Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Abbott Laboratories
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Astellas Pharma Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives